Christi Kim

Medical Oncologist, Breast & Gynecologic cancers

[Christi Kim @ChristiKimMD]

TDXd + Pertuzumab for First line HER2+ Metastatic Breast Cancer | NEJM. DB-09
Now FDA approved!
mPFS 40.7 mo (vs 26.9 mo in CLEOPATRA), ORR 85.1% (vs 78.6%), 58 CR (vs 33).
Bring ADC to First line HER2+ mBC.
Potentially curing more patients!
https://t.co/j29TKscEVW

[Christi Kim @ChristiKimMD]

FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma regardless of MMR status (NRG-GY018) https://t.co/tixqLFfFx3

[Christi Kim @ChristiKimMD]

FDA approves dostarlimab-gxly with chemotherapy for ALL Advanced endometrial cancer https://t.co/WXPZs0KAbU

[Christi Kim @ChristiKimMD]

FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 Stage III-IVA cervical cancer https://t.co/3sUnxenOea

[Alireza Dolatshahi-Pirouz @aldo369369369]

To achieve success and fulfill your dreams, you need to take action. Thinking about it alone cannot lead you to your goals and aspirations. It is essential to sit down and devise a plan, but then you must act upon it.

Yes you will fail. You will crash and burn yourself several times. But this is how you learn and grow stronger. There is nothing wrong about failing. Don’t fear that. You learn from your mistakes. Just do it!

So stop overthinking. Say yes to life - seize the day and push forward. As Churchill famously said, when all hell breaks loose don’t look back just keep going.

#keepgoing #fastfullforward #justdoit #overthinking #mentalhealthmatters #mentalstrength

[Alireza Dolatshahi-Pirouz @aldo369369369]

When the going gets tough, keep going. You will fall down and hurt yourself many times, but eventually, you will grow stronger and better. Remember, you learn through your failures - this is the best learning curve that life has to offer. So, seize it, do it, adjust, and push it.

#pushyourlimits #seizetheday #sayyestolife #fastfullforward #keepgoing

[Alireza Dolatshahi-Pirouz @aldo369369369]

She wrote all the computer codes for the Apollo 11 Moon landing.

Her name was Margaret Hamilton.

In the picture Margaret is standing beside all the codes that she made for the Apollo 11 mission.

More women in science please!

#WomenInSTEM #WomenWhoCode #womeninscience #womeninengineering

[Christi Kim @ChristiKimMD]

Trastuzumab Deruxtecan in HER2+ in Solid Tumors amazing responses in Cervical, Uterine, Ovary, Bladder DESTINY-PanTumor02
ORR: 50% (cervix), 57% (uterus), 45% (ov)
CR: 5% (cervix), 17.5% (uterus), 10% (ov)
mDOR: 9.8 mo (cervix), NR (uterus), 11.3 mo (ov) #ASCO23 @ASCO #gyncancer

[Christi Kim @ChristiKimMD]

Practice changing Nivo + AVD in advanced classic Hodgkin Lymphoma, SWOG S1826: nivolumab-AVD versus brentuximab vedotin(BV)-AVD #ASCO23 @ASCO #Hodgkins #lymphoma

[Christi Kim @ChristiKimMD]

KRYSTAL-1 data: Adagrasib promising activity in KRAS G12C-mutated Ovarian and Endometrial cancers. Needs tumor testing. No one left behind. #ASCO23 #ovariancancer #UterineCancer

[Kai @bmassutis]

Individualized neoantigen vaccine add to Pembro in adjuvant Melanoma setting increase significantly DFS at #AACR2023 @OncoAlert

[Tyler Johnson @tpjmd]

I can attest that few practice mentoring more meaningfully than @PamelaKunzMD.

Her greatness comes from many places, but nowhere more so than from the success of those she pushes into the spotlight.

She will spend her career quietly seeing her mentees magnify what she teaches.

[AACR Foundation @AACRFoundation]

.@AACR President-Elect 2023-2024 Dr. Patricia M. LoRusso: “I always look at cancer as my enemy. It’s been my enemy for many, many years.” Her experiences led her to pursue a career focused on helping to develop new cancer treatments. https://t.co/YO8vED3yQw

[Christi Kim @ChristiKimMD]

Long waited RUBY trial update: addition of Dortalimab to chemo in advanced or recurrent endometrial cancer significantly improves PFS & early OS trend in overall population @ESMO @SGO_org #SGOmtg #SGO23 #PatientsPurposeProgress

[Christi Kim @ChristiKimMD]

Practice changing NRG-GY018: addition of Pembrolizumab to chemo significantly improves PFS regardless of MMR status in stage III/IVA or IVB or recurrent metastatic endometrial cancer. Immense gratitude to investigators & patients @SGO_org #SGOMtg #SGO23 #PatientsPurposeProgress

[Christi Kim @ChristiKimMD]

GOG-3026 Ribociclib + Letrozole in Recurrent low-grade serous carcinoma of ovary (LGSOC), 27% patients already had prior hormonal therapy: ORR 23%, CBR 79%, DOR 19.1 months, #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress

[Christi Kim @ChristiKimMD]

Neoadjuvant Olaparib WINDOW Trial in Newly diagnosed BRCA mutant high grade serous ovarian cancer (including RAD51C, PALB2): 53% PR, 46% SD, 0% PD, 1 patient with pathological CR, 85% no gross residual dz, 14% < 1cm residual. #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress

[Christi Kim @ChristiKimMD]

Era of molecular subclassifications in EC: Molecular predictor (MMR, p53) under evaluation, #PatientsPurposeProgress

[Christi Kim @ChristiKimMD]

NRG GOG-238 update - No Survival benefit with addition of radiation therapy to chemotherapy in any subgroup in stage III - IVA endometrial cancer, #SGOmtg, #SGO2023, #endometrialcancer

[NRG Oncology @NRGonc]

PRESS RELEASE: NRG Oncology NRG-GY018 Study Demonstrates Significantly Improved Progression-Free Survival Outcomes for Women with Advanced or Recurrent #EndometrialCancer with the Addition of Pembrolizumab to #Chemotherapy - Read more: https://t.co/oZc1glGIRz